Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)
3301 Agriculture Drive
250 articles with Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)
2/24/2020Mid-February had a solid number of clinical trial announcements. Here’s a look.
12/23/2019Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
12/16/2019It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
It was another busy week for clinical trials. Here’s a look.
9/23/2019Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Cellectar Biosciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation for CLR 131 in relapsed or refractory Diffuse Large B-Cell Lymphoma.
Cellectar Initiates DLBCL Cohort in Phase II Trial of CLR 131 in Refractory B-Cell Hematologic Cancers
The Company expects to enroll up to 10 patients with DLBCL into this cohort prior to conducting an interim analysis.
Cellectar Biosciences is closing its manufacturing operations and contracting them out.
The study will be initiated with the pediatric oncologists and Nuclear Medicine/Radiology Group at The University of Wisconsin Carbone Cancer Center.
Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase II Trial of CLR 131
Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit.
Cash and cash equivalents as of September 30, 2017 were approximately $5.7 million compared to approximately $11.4 million as of December 31, 2016.
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase I Trial in Advanced Multiple Myeloma
While no head-to-head studies have been conducted for comparison, the median overall survival benefit seen with the three most recently FDA-approved third line therapies for multiple myeloma ranges from 11.9 – 18.6 months in separate trials.
Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance
The live and archived webcast can be accessed via the company’s website
New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination With External Radiation
Investigators observed that CLR 127 was taken up and retained in the tumor cells at 6-10 fold higher level than normal tissue and sensitized the tumor cells to external radiation.
Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma
In September, the trial's Data Monitoring Committee (DMC) determined that the fourth cohort single dose of 31.25 mCi/m2 was safe and tolerated.
Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors
The Japanese Patent Office has granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125.
Cellectar Biosciences And Pierre Fabre Extend Collaboration For Development Of New Phospholipid Drug Conjugates